8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 5, 2026·SEC
Material company update
Jan 23, 2026·SEC
NextCure, Inc.(NXTC)Earnings, Financials & Key Ratios
NXTC•NASDAQ
$1.65
Price updated Jun 27, 2026
AboutNextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.Show more
- Revenue$0
- EBITDA-$55M+2.6%
- Net Income-$56M-0.3%
- EPS (Diluted)-19.65+17.7%
- ROE-111.23%-79.8%
NXTC Price & Volume
NextCure, Inc. (NXTC) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Future Capital Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Critical Cash Runway Depletion
Key Thesis Takeaways
- NextCure faces a precarious outlook as it continues to operate without revenue, leading to a rapid erosion of its asset base from $128.0 million in 2023Q4 to $38.0 million in 2026Q1.
- The company's reliance on external funding to support volatile R&D expenditures, which peaked at $24.1 million in 2025Q2, suggests a high probability of further shareholder dilution.
- Investors should monitor the company's ability to secure strategic partnerships, as current cash reserves of $15.2 million appear insufficient to sustain long-term clinical development.
Verdict Logic
the company's liquidity buffer has plummeted to $15.2 million as of 2026Q1, indicating a high risk of forced capital raises that would likely dilute existing shareholders.
NXTC Growth Metrics
NextCure, Inc. (NXTC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-10.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM10.19%
Return on Capital
10 Years-47.68%
5 Years-55.04%
3 Years-70.56%
Last Year-103.9%
Peers Comparison
Key metrics vs top competitors for NextCure, Inc. (NXTC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.65 | $4.41M | -0.08 | — | — | -111.23% | — | |
| $2.10 | $244.77M | -1.83 | -51.24% | -2056.79% | -58.89% | — | |
| $31.00 | $3.12B | -9.42 | -4.26% | -156.36% | -68.97% | — | |
| $3.03 | $126.18M | -891.18 | 10.37% | 52.16% | — | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $55.83 | $8.55B | 20.16 | 87.32% | 65.95% | 87.36% | — |
Compare NXTC vs Peers
NextCure, Inc. (NXTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NXTC SEC Filings & Documents
NextCure, Inc. (NXTC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when NXTC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NXTC Frequently Asked Questions
NextCure, Inc. (NXTC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is NXTC profitable?
NextCure, Inc. (NXTC) reported a net loss of $54.7M for fiscal year 2025.
Dividend & Returns
What is NXTC's return on equity?
NextCure, Inc. (NXTC) has a return on equity (ROE) of -111.2%. Negative ROE indicates the company is unprofitable.
What is NextCure, Inc.'s free cash flow?
NextCure, Inc. (NXTC) had negative free cash flow of $50.0M in fiscal year 2025, likely due to heavy capital investments.